Package Leaflet: Information for theuser
Atazanavir Viatris 150 mg hard capsulesEFG
Atazanavir Viatris 200 mg hard capsulesEFG
Atazanavir Viatris 300 mg hard capsulesEFG
atazanavir
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of thepackage leaflet
1. What Atazanavir Viatris is and what it is used for
2. What you need to know before you take Atazanavir Viatris
3. How to take Atazanavir Viatris
4. Possible side effects
5. How to store Atazanavir Viatris
6. Contents of the pack and other information
Atazanavir Viatris is an antiviral medicine (or antiretroviral).It belongs to a group of medicines called protease inhibitors.These medicines control HIV infection by blocking a protein that HIV needs to multiply. It works by reducing the amount of HIV in your body and thereby strengthening your immune system. This reduces the risk of developing diseases associated with HIV infection.
Atazanavir Viatris capsules can be used by adults and children aged 6 years and over. Your doctor has prescribed Atazanavir Viatris because you are infected with HIV, which causes acquired immune deficiency syndrome (AIDS). It is usually used in combination with other anti-HIV medicines. Your doctor will decide which combination of medicines is best for you.
Do not take AtazanavirViatris
(listed in section 6)
Do not take sildenafil with Atazanavir Viatris when sildenafil is used to treat pulmonary arterial hypertension. Sildenafil is also used to treat erectile dysfunction. Inform your doctor if you are using sildenafil to treat erectile dysfunction.
Inform your doctor immediately if you are in any of these situations.
Warnings andprecautions
Atazanavir Viatris is not a cure for HIV infection.You may still develop infections or other illnesses associated with HIV. Some people may need special monitoring before or during treatment with Atazanavir Viatris. Consult your doctor or pharmacist before starting Atazanavir Viatris and make sure to inform your doctor:
Atazanavir may affect kidney function.
There have been reports of kidney stones in patients treated with atazanavir. If you experience signs or symptoms of kidney stones (side pain, blood in the urine, pain when urinating), please inform your doctor immediately.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections, signs and symptoms of inflammation of previous infections may appear after starting anti-HIV treatment. These symptoms are thought to be due to an improvement in the body's immune response, allowing it to fight infections that were present without any apparent symptoms. If you notice any symptoms of infection, please inform your doctor immediately. In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also appear after you start taking medicines to treat your HIV infection. Autoimmune disorders may appear many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremors, or hyperactivity, please inform your doctor immediately to receive the necessary treatment.
Some patients receiving combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Among the many risk factors for developing this disease are the duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immunodepression, and high body mass index. The symptoms of osteonecrosis are joint stiffness, pain, and discomfort (especially in the hip, knee, and shoulder) and difficulty moving. If you notice any of these symptoms, please inform your doctor.
Hyperbilirubinemia (elevated bilirubin levels in the blood) has occurred in patients receiving atazanavir. The signs may be a slightly yellowish tint to the skin or eyes. If you notice any of these symptoms, please inform your doctor.
Severe skin rash, including Stevens-Johnson syndrome, has been observed in patients treated with atazanavir. Inform your doctor immediately if you develop a rash.
If you notice a change in the way your heart beats (changes in heart rhythm), please inform your doctor.
Children receiving Atazanavir Viatris may require their heart to be monitored. Your child's doctor will decide this.
Children
Do not give this medicine to childrenunder 3 months of age and weighing less than 5 kg. The use of atazanavir has not been studied in children under 3 months of age and weighing less than 5 kg due to the risk of serious complications.
Other medicines and AtazanavirViatris
You must not take Atazanavir Viatris with certain medicines. These are listed under the heading Do not take Atazanavir Viatrisat the beginning of Section 2.
There are other medicines that should not be taken with Atazanavir Viatris. Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. It is especially important that you mention the use of the following:
Some medicines may interact with ritonavir, a medicine that is given with Atazanavir Viatris. It is important that you inform your doctor if you are using fluticasone or budesonide (administered by nasal or inhalation route, for the treatment of allergic symptoms or asthma).
Taking Atazanavir Viatris with food anddrinks
It is important that you take Atazanavir Viatris with food (a meal or snack) as this helps the absorption of the medicine.
Pregnancy andbreast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Atazanavir, the active substance of Atazanavir Viatris, is excreted in human milk. You should also talk to your doctor about breast-feeding. Patients must not breast-feed while taking Atazanavir Viatris. It is recommended that HIV-infected women do not breast-feed their babies because the virus can be transmitted through breast milk.
It is not recommendedthat women living with HIV breast-feed their babies because HIV infection can be transmitted through breast milk.
If you are breast-feeding or thinking of breast-feeding, you should consult your doctoras soon as possible.
Driving and usingmachines
If you feel dizzy or drowsy, do not drive or use machines, and contact your doctor immediately.
Atazanavir Viatris containslactose.
If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Follow exactly the instructions of your doctor or pharmacist. If you are unsure, consult your doctor. This way, you can be sure that the treatment is fully effective and reduces the risk of the virus developing resistance to the treatment.
The recommended dose of Atazanavir Viatris capsules for adults is 300 mg together with 100mgof ritonavir once daily and with food,in combination with other anti-HIV medicines. Your doctor may adjust the dose of Atazanavir Viatris according to your anti-HIV treatment.
For children (from 6 to less than 18 years of age), your child's doctor will decide thedosebased on your child's weight.The dose of Atazanavir Viatris capsules for children is calculated by body weight and taken once daily with food and 100 mg of ritonavir as shown below:
BodyWeight (kg) | Dose of AtazanavirViatrisonce daily(mg) | Dose of ritonavir*oncedaily(mg) |
15 to less than 35 | 200 | 100 |
35 or more | 300 | 100 |
|
Other forms of this medicine may be available for use in children aged 3 months or older and weighing 5 kg or more. It is recommended to switch to other formulations as soon as patients are able to swallow the capsules properly.
When switching between other formulations and capsules, a dose change may be necessary. Your doctor will decide the correct dose based on your child's weight. There are no dose recommendations for Atazanavir Viatris in pediatric patients under 3 months of age.
Take Atazanavir Viatris capsules with food(a meal or snack). Swallow the capsules whole. Do not open thecapsules.
If you take more Atazanavir Viatris than youshould
If you or your child take too much Atazanavir Viatris, the skin and/or eyes may turn yellow (jaundice) and irregular heartbeats (prolonged QTc) may occur. If you have accidentally taken more Atazanavir Viatris capsules than your doctor recommended, contact your doctor immediately or go to the nearest hospital for consultation.
If you forget to take AtazanavirViatris
If you have missed a dose, take it as soon as possible with some food, and then take the next dose at the usual time. If it is almost time for the next dose, do not take the missed dose. Wait and take the next dose at the usual time. Do not take a double dose to make up formisseddoses.
If you stop taking AtazanavirViatris
Do not stop taking Atazanavir Viatris without consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. During the treatment of HIV infection, it is not always easy to identify the adverse effects caused by atazanavir, by any other medicine you are taking, or by the HIV infection itself. Inform your doctor of any change you notice in your state of health.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes with HIV medicines themselves. Your doctor will monitor these changes.
Inform your doctor immediately if you develop any of the following serious adverse effects:
Other adverse effects reported in patients treated with atazanavir are the following:
Frequent (may affect up to 1 in 10 people):
Infrequent (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V.
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the label, carton, or blister. The expiration date is the last day of the month indicated.
Store below 25°C. Store in the original packaging to protect from moisture.
In the case of bottles: Once opened, use the medicine within 90 days.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Atazanavir Viatris
Atazanavir Viatris 150 mg hard capsules
Atazanavir Viatris 200 mg hard capsules
Atazanavir Viatris 300 mg hard capsules
Appearance of Atazanavir Viatris and Package Contents
Atazanavir Viatris 150 mg hard capsules are greenish-blue and blue opaque capsules with the imprint "MYLAN" over "AR150" in black ink on the cap and body.
Atazanavir Viatris 200 mg hard capsules are blue and greenish-blue opaque capsules with the imprint "MYLAN" over "AR200" in black ink on the cap and body.
Atazanavir Viatris 300 mg hard capsules are red and greenish-blue opaque capsules with the imprint "MYLAN" over "AR300" in black ink on the cap and body.
Atazanavir Viatris 150 mg hard capsules
This medicine is supplied in blisters containing 60 or 60 x 1 (single-dose) capsules or in bottles containing 60 hard capsules.
Atazanavir Viatris 200 mg hard capsules
This medicine is supplied in blisters containing 30, 60, or 60 x 1 (single-dose) capsules or in bottles containing 60 hard capsules.
Atazanavir Viatris 300 mg hard capsules
This medicine is supplied in blisters containing 30 or 30 x 1 (single-dose) capsules or in bottles containing 30 or 90 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland
Manufacturers
Mylan Hungary Kft, Mylan utca 1, Komárom, H-2900 Hungary
Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1, Bad Homburg v. d. Hoehe, Hessen, 61352, Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Viatris Tél/Tel: + 32 (0)2 658 61 00 | Lietuva Viatris UAB Tel: +370 5 205 1288 |
Luxembourg/Luxemburg Viatris Tél/Tel: + 32 (0)2 658 61 00 (Belgique/Belgien) | |
Česká republika Viatris CZ.s.r.o. Tel: + 420 222 004 400 | Magyarország Viatris Healthcare Kft. Tel.: + 36 1 465 2100 |
Danmark Viatris ApS Tlf.: + 45 28 11 69 32 | Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 74 |
Deutschland Viatris Healthcare GmbH Tel: + 49 800 0700 800 | Nederland Mylan B.V. Tel: + 31 (0)20 426 3300 |
Eesti Viatris OÜ Tel: + 372 6363 052 | Norge Viatris AS Tlf: + 47 66 75 33 00 |
Ελλάδα Viatris Hellas Ltd Τηλ: +30 2100 100 002 | Österreich Viatris Austria GmbH Tel: + 43 1 86390 |
España Viatris Pharmaceuticals, S.L. Tel: + 34 900 102 712 | Polska Viatris Healthcare Sp. z.o.o. Tel.: + 48 22 564 64 00 |
France Viatris Santé Tél: +33 4 37 25 75 00 | Portugal Mylan, Lda. Tel: +351 214 127 200 |
Hrvatska Viatris Hrvatska d.o.o. Tel: +385 1 23 50 599 | România BGP Products SRL Tel: + 40 372 579 000 |
Ireland Viatris Limited Tel: +353 1 8711600 | Slovenija Viatris d.o.o. Tel: +386 1 236 31 80 |
Ísland Icepharma hf. Sími: +354 540 8000 | Slovenská republika Viatris Slovakia s.r.o. Tel: +421 2 32 199 100 |
Italia Viatris Italia S.r.l. Tel: +39 02 612 46921 | Suomi/Finland Viatris Oy Puh/Tel: +358 20 720 9555 |
Κύπρος CPO Pharmaceuticals Limited Τηλ: + 357 22863100 | Sverige Viatris AB Tel: + 46 (0) 8 630 19 00 |
Latvija Viatris SIA Tel: + 371 676 055 80 |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.